News | February 17, 2026
Indian pharma market grew 10.2% yoy in January 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Price was the key driver for the period
Acute therapies continue to report strong growth compared to chronic ones.
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Demand normalisation post the second wave contributed to the steady growth
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Subscribe To Our Newsletter & Stay Updated
